Dangerous Drug: Liraglutide(lir ah gloo’ tide)
Victoza
PREGNANCY CATEGORY C
Drug Classes
Antidiabetic
Glucagon-like peptide receptor agonist
Therapeutic Actions
Increases intracellular cyclic AMP in pancreatic beta cells, leading to insulin release in the presence of elevated glucose concentrations; this insulin secretion subsides as blood glucose levels approach normal; it also decreases glucagon secretion in a glucose-dependent manner; this mechanism of glucose lowering also causes a delay in gastric emptying, helping to achieve glucose control.
Indications
As adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to liraglutide, personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome (MENS) type 2, type 1 diabetes, diabetic ketoacidosis.
Use cautiously with pancreatitis, pregnancy, lactation.
Available Forms
Solution for injection in prefilled pens—6 mg/mL (delivers 0.6, 1.2, or 1.8 mg)
Dosages
Adults
Initially, 0.6 mg by subcutaneous injection once a day, without regard to meals, for 1 wk; then increase to 1.2 mg/day by subcutaneous injection. May be increased to 1.8 mg/day if needed.
Pediatric patients
Safety and efficacy not established.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
